We are live on ! Find out more
KCA

KVP Capital Advisors Portfolio holdings

AUM $136M
This Fund
S&P 500
This Quarter Est. Return
+25.27%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
+$2.34M
Cap. Flow
-$18.6M
Cap. Flow %
-13.67%
Top 10 Hldgs %
57.41%
Holding
38
New
6
Increased
2
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$5.26M
2
AVBP icon
ArriVent BioPharma
AVBP
+$3.01M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$2.31M
4
DSGN icon
Design Therapeutics
DSGN
+$2.31M
5
ARTV
Artiva Biotherapeutics
ARTV
+$1.82M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$23.2M
2
AXSM icon
Axsome Therapeutics
AXSM
+$5.25M
3
RVMD icon
Revolution Medicines
RVMD
+$3.91M
4
TVTX icon
Travere Therapeutics
TVTX
+$2.31M
5
SLNO
Soleno Therapeutics
SLNO
+$2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
1
Praxis Precision Medicines
PRAX
$9.63B
$14.4M 10.54%
42,900
– –
WHWK
2
Whitehawk Therapeutics
WHWK
$263M
$9.92M 7.28%
2,165,997
– –
ERAS icon
3
Erasca
ERAS
$6.31B
$8.34M 6.12%
455,000
+115,000
+34% +$1.64M
TRVI icon
4
Trevi Therapeutics
TRVI
$2.39B
$7.72M 5.67%
414,000
– –
STRO icon
5
Sutro Biopharma
STRO
$339M
$7.52M 5.52%
226,575
– –
TNGX icon
6
Tango Therapeutics
TNGX
$3.94B
$7.2M 5.28%
230,264
– –
MBX
7
MBX Biosciences
MBX
$3.03B
$6.71M 4.92%
121,524
– –
PTGX icon
8
Protagonist Therapeutics
PTGX
$9.34B
$6.5M 4.77%
53,000
– –
EWTX icon
9
Edgewise Therapeutics
EWTX
$4.64B
$5.4M 3.97%
133,000
– –
TNDM icon
10
Tandem Diabetes Care
TNDM
$1.49B
$4.54M 3.33%
+301,000
New +$5.26M
IRON icon
11
Disc Medicine
IRON
$3.07B
$4.26M 3.13%
58,250
– –
SVRA icon
12
Savara
SVRA
$1.08B
$3.73M 2.74%
605,280
– –
AVBP icon
13
ArriVent BioPharma
AVBP
$1.49B
$3.54M 2.6%
+102,000
New +$3.01M
INSM icon
14
Insmed
INSM
$25.9B
$3.04M 2.23%
28,497
– –
ACHV icon
15
Achieve Life Sciences
ACHV
$834M
$3.02M 2.22%
462,355
– –
IDYA icon
16
IDEAYA Biosciences
IDYA
$3.87B
$2.97M 2.18%
79,700
– –
OCUL icon
17
Ocular Therapeutix
OCUL
$2.28B
$2.95M 2.16%
300,000
– –
AXSM icon
18
Axsome Therapeutics
AXSM
$10.4B
$2.94M 2.16%
12,000
-24,200
-67% -$5.25M
DSGN icon
19
Design Therapeutics
DSGN
$946M
$2.68M 1.96%
+185,000
New +$2.31M
UTHR icon
20
United Therapeutics
UTHR
$22.1B
$2.57M 1.89%
4,750
– –
SRRK icon
21
Scholar Rock
SRRK
$7.04B
$2.48M 1.82%
45,000
– –
IMMX icon
22
Immix Biopharma
IMMX
$992M
$2.38M 1.74%
230,423
– –
VRDN icon
23
Viridian Therapeutics
VRDN
$2.61B
$2.3M 1.69%
125,000
– –
MLYS icon
24
Mineralys Therapeutics
MLYS
$2.26B
$2.27M 1.67%
+84,168
New +$2.31M
DRUG
25
Bright Minds Biosciences
DRUG
$714M
$2.23M 1.64%
31,813
– –
1
2

Similar funds

RC
Rahlfs Capital Lake Kiowa, Texas $136M AUM 33.89% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $136M AUM 23.45% 1-Year Est. Return
SB
Semitam Bonam Goshen, New York $136M AUM 13.42% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
FEM
Fulcrum Equity Management Plano, Texas $136M AUM 42.95% 1-Year Est. Return
SCM
Sidoxia Capital Management Newport Beach, California $136M AUM
VSCP
Vesey Street Capital Partners New York $136M AUM 6.83% 1-Year Est. Return

KVP Capital Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, KVP Capital Advisors held 38 positions worth $136M, up 1.7% from $134M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

KVP Capital Advisors withdrew a net $18.6M in Q2 2026, closing 3 positions and reducing 2 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $23.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, KVP Capital Advisors opened a new position in Tandem Diabetes Care worth $4.54M.

  • KVP Capital Advisors's largest Q2 2026 buy was Tandem Diabetes Care: 301,000 shares worth $4.54M.
  • KVP Capital Advisors added most to Erasca in Q2 2026, an estimated $1.64M increase.
  • KVP Capital Advisors's biggest Q2 2026 reduction was Axsome Therapeutics, cutting an estimated $5.25M.
  • KVP Capital Advisors fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $23.2M.
  • KVP Capital Advisors's ten largest holdings make up 57% of its $136M portfolio in Q2 2026.
  • KVP Capital Advisors opened 6 new positions and closed 3 in Q2 2026.
  • KVP Capital Advisors's portfolio value rose 1.7% quarter-over-quarter to $136M.

Based on KVP Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.